DIAGNOSTIC ADJUNCTS TO CYTOPATHOLOGICAL DIAGNOSIS

细胞病理学诊断的辅助诊断

• 批准号: 2464426
• 负责人: A ABATI
• 金额: --
• 依托单位: DIVISION OF CLINICAL SCIENCES - NCI
• 依托单位国家: 美国
• 资助国家: 美国
• 起止时间: 至
• 项目状态: 未结题
• 来源: https://reporter.nih.gov/project-details/2464426
• 关键词: adolescence (12-20); biomarker; breast neoplasms; child (0-11); clinical research; cytodiagnosis; fine needle aspiration; human subject; human tissue; immunocytochemistry; lymphoma; melanoma; neoplasm /cancer diagnosis; tumor antigens

Immunocytochemistry has proved to be a valuable diagnostic adjunct to cytopathologic diagnosis. The Cytopathology Section is involved in several clinically-related research projects, many of which utilize fine needle aspiration (FNA) and immunocytochemistry to provide ancillary diagnostic information regarding expression of various tumor antigens, HLA antigens or other markers. A partial listing of such studies includes: (1) Evaluation of percent of tumor cells expressing CD22 and CD19 in FNA specimens as part of a clinical trial using monoclonal antibody therapy for refractory lymphomas; (2) Evaluation of expression of drug resistance marker P-glycoprotein prospectively by FNA in breast cancer patients treated with new combination chemotherapy; (3) Cytologic diagnosis and immunophenotyping of ocular lymphomas; (4) characterization and application of a novel murine monoclonal antibody for malignant melanoma, MART-1 with subsequent quantitation of MART-1 in FNAs from malignant melanoma patients for treatment with anti-MART-1 antibody; (5) morphologic and immunocytochemical evaluation of bone marrow and peripheral blood samples for the detection of malignant cells in patients with stage IV breast cancer; (6) cytologic and immunocytochemical analysis of anaplastic large cell lymphomas.

免疫细胞化学已被证明是一种有价值的诊断辅助手段， 细胞病理学诊断 细胞病理学科参与了 几个临床相关的研究项目，其中许多利用罚款 针吸活检（FNA）和免疫细胞化学提供辅助 关于各种肿瘤抗原、HLA的表达的诊断信息 抗原或其它标记物。 这些研究的部分清单包括： (1)FNA中表达CD 22和CD 19的肿瘤细胞百分比的评价 作为单克隆抗体治疗临床试验一部分的标本 难治性淋巴瘤;（2）评价耐药性的表达 FNA检测乳腺癌患者P-糖蛋白的前瞻性研究 新联合化疗;（3）细胞学诊断， 眼淋巴瘤的免疫表型;（4）表征和 一种新的抗恶性黑色素瘤鼠单克隆抗体的应用， MART-1以及随后对来自恶性肿瘤的FNA中的MART-1进行定量 用抗MART-1抗体治疗的黑素瘤患者;（5）形态学 骨髓和外周血的免疫细胞化学评价 用于检测IV期患者恶性细胞的样本 乳腺癌;（6）间变性的细胞学和免疫细胞化学分析 大细胞淋巴瘤